Skip to main
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is poised for success with their novel therapy, LB-102, as it has shown promising results in Phase 2 trials and has potential for treatment of multiple neuropsychiatric disorders. With a favorable safety profile and potential partnerships with other pharmaceutical companies, the company has a positive outlook for its drug's success. The company also has enough funding to continue operations for several years and has a projected target price for their stock, making it an attractive investment opportunity.

Bears say

LB Pharmaceuticals is facing potential difficulties in obtaining regulatory approvals for its pipeline drugs, including its late-stage compound LB-102, and navigating the increasingly challenging reimbursement landscape. The company faces significant competition in both schizophrenia and depression markets, and its late entry into these markets may hinder its ability to capture a significant portion of the market share. The high commercial potential projected for LB-102 may not be fully realized if the company faces challenges in obtaining regulatory approval and effectively marketing its drug.

LBRX has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Buy based on their latest research and market trends.

According to 7 analysts, LBRX has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.